Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Pfizer Inc (CIK 78003) reported $170.4M across 17 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: ALLO ($46.9M, 27.55%), CELC ($29.6M, 17.35%), ARVN ($27.7M, 16.24%), PYXS ($19.5M, 11.43%), WVE ($10.9M, 6.42%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ALLO | ALLOGENE THERAPEUTICS INC | $46.9M | 27.55% | 22.0M | Hold |
| 2 | CELC | CELCUITY INC | $29.6M | 17.35% | 295,652 | Hold |
| 3 | ARVN | ARVINAS INC | $27.7M | 16.24% | 3.5M | Hold |
| 4 | PYXS | PYXIS ONCOLOGY INC | $19.5M | 11.43% | 7.0M | Hold |
| 5 | WVE | WAVE LIFE SCIENCES LTD | $10.9M | 6.42% | 1.9M | Hold |
| 6 | BHVN | BIOHAVEN LTD | $8.0M | 4.70% | 505,645 | Hold |
| 7 | CRBU | CARIBOU BIOSCIENCES INC | $7.9M | 4.63% | 4.7M | Hold |
| 8 | SPRO | SPERO THERAPEUTICS INC | $5.3M | 3.13% | 2.4M | Hold |
| 9 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $3.9M | 2.26% | 953,834 | Hold |
| 10 | ORIC | ORIC PHARMACEUTICALS INC | $3.6M | 2.09% | 372,904 | Trimmed |
| 11 | CRDF | CARDIFF ONCOLOGY INC | $3.0M | 1.77% | 2.4M | Hold |
| 12 | ZURA | ZURA BIO LTD | $2.9M | 1.69% | 538,841 | Trimmed |
| 13 | AGMB | AGOMAB THERAPEUTICS NV | $1.0M | 0.61% | 75,000 | Hold |
| 14 | BOLT | BOLT BIOTHERAPEUTICS INC | $133,832 | 0.08% | 31,305 | Hold |
| 15 | NXTC | NEXTCURE INC | $72,967 | 0.04% | 44,347 | Trimmed |
| 16 | DNA | GINKGO BIOWORKS HOLDINGS INC | $30,012 | 0.02% | 2,928 | Hold |
| 17 | SENS | SENSEONICS HLDGS INC | $12,418 | 0.01% | 2,171 | Hold |
| 18 | QTTB | Q32 BIO INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30